What the new the Netherlands guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Salomé Adeyemi
Page 10 of 13 of this archive, newest first.
Archive — page 10
243 piecesWhat the new Singapore guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new India guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The incretin receptors, ranked by how much we actually know about them
The receptor is expressed in more tissues than the popular account allows, and that is the whole story.
Discontinuation rates, read honestly
An effect is dose-limiting when it prevents adequate intake, prevents normal activity, or produces a risk of its own. Discomfort alone is not the test.
Do you need the top of the ladder?
A plateau at an intermediate dose and a plateau at the maximum dose look identical from the outside and mean different things.
What the new the United Arab Emirates guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Singapore guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Brazil guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What competing on one number does to a market
A market that competes on one measurement will optimise that measurement. There are legitimate ways to raise a purity figure that involve no change to the product at all.
What the new Ireland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Argentina guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Canada guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The half-life question, answered properly
What the pharmacokinetic data supports about dose timing, missed doses and interruption.
What “LC-MS: conforms” tells a reader, which is almost nothing
The regulated world states the method, the instrument, the convention and the tolerance. This market states a verdict.
What the new New Zealand guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Turkey guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Pancreatitis, obstruction, gallbladder: three things nausea can be
The features that should prompt urgent assessment, stated once and plainly.
What the new Poland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Nigeria guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.